Since the cause of PMF is primarily idiopathic, treatment is targeted toward the symptoms that are being displayed. If a patient is currently asymptomatic, then treatment is reserved until symptoms become evident. Some of these symptomatic treatments include:
- Blood transfusions for severe anemia
- Platelet transfusions for thrombocytopenia caused by splenomegaly
- Immunosuppressant drugs such as hydroxyurea or busulfan to suppress bone marrow's overproduction of cells
The FDA has approved two drugs, ruxolitinib and fedratinib, to treat patients with intermediate or high-risk myelofibrosis. These drugs inhibit the JAK 1 and 2 enzymes.
